Cathelicidin LL-37 bloodstream surveillance is down regulated during septic shock
Carregando...
Citações na Scopus
30
Tipo de produção
article
Data de publicação
2013
Editora
ELSEVIER SCIENCE BV
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
MICROBES AND INFECTION, v.15, n.5, p.342-346, 2013
Resumo
Host defense peptides are ancient weapons of the innate immunity. The human cathelicidin LL-37 protects the epithelial barrier against infection and is constitutively secreted in the bloodstream by immune cells. Current knowledge claims that LL-37 is up regulated upon infection. LL-37 can protect against bacterial infections and possesses many immunomodulatory properties. Here, we show that the human host defense peptide LL-37 is down regulated during septic shock. Furthermore, we show that these effects are not related to vitamin D serum levels, a potent inducer of LL-37 gene expression, pointing out the complex regulation of cathelicidins during septic shock.
Palavras-chave
Cathelicidin, Vitamin D, Inflammation
Referências
- Bals R, 1999, INFECT IMMUN, V67, P6084
- Berkestedt I, 2010, J INNATE IMMUN, V2, P478, DOI 10.1159/000317036
- BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644
- Bowdish DME, 2005, CURR PROTEIN PEPT SC, V6, P35, DOI 10.2174/1389203053027494
- Bowdish DME, 2004, J IMMUNOL, V172, P3758
- Brown KL, 2011, J IMMUNOL, V186, P5497, DOI 10.4049/jimmunol.1002508
- Carretero M, 2008, J INVEST DERMATOL, V128, P223, DOI 10.1038/sj.jid.5701043
- Chromek M, 2006, NAT MED, V12, P636, DOI 10.1038/nm1407
- Cirioni O, 2006, ANTIMICROB AGENTS CH, V50, P1672, DOI 10.1128/AAC.50.5.1672-1679.2006
- da Silva FP, 2012, PEPTIDES, V36, P308, DOI 10.1016/j.peptides.2012.05.014
- da Silva FP, 2009, IMMUNOL CELL BIOL, V87, P496, DOI 10.1038/icb.2009.19
- Dorschner RA, 2001, J INVEST DERMATOL, V117, P91, DOI 10.1046/j.1523-1747.2001.01340.x
- Hancock REW, 2012, NAT REV MICROBIOL, V10, P243, DOI 10.1038/nrmicro2745
- Huang LC, 2007, CURR EYE RES, V32, P595, DOI 10.1080/02713680701446653
- Iimura M, 2005, J IMMUNOL, V174, P4901
- Jeng L, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-28
- Koczulla R, 2003, J CLIN INVEST, V111, P1665, DOI 10.1172/JCI200317545
- Kurosaka K, 2005, J IMMUNOL, V174, P6257
- Lee CC, 2011, BIOPHYS J, V100, P1688, DOI 10.1016/j.bpj.2011.02.018
- Liu PT, 2006, SCIENCE, V311, P1770, DOI 10.1126/science.1123933
- Mookherjee N, 2007, EXPERT OPIN THER TAR, V11, P993, DOI 10.1517/14728222.11.8.993
- Mookherjee N, 2006, J IMMUNOL, V176, P2455
- Ng G, 2008, IMMUNITY, V29, P807, DOI 10.1016/j.immuni.2008.09.013
- Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587
- Oppenheim JJ, 2007, ADV EXP MED BIOL, V601, P185
- Oppenheim JJ, 2005, CURR OPIN IMMUNOL, V17, P359, DOI 10.1016/j.coi.2005.06.002
- Oren Z, 1999, BIOCHEM J, V341, P501, DOI 10.1042/0264-6021:3410501
- Schauber J, 2006, IMMUNOLOGY, V118, P509, DOI 10.1111/j.1365-2567.2006.02399.x
- Scott A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026525
- Scott MG, 2002, J IMMUNOL, V169, P3883
- Zheng Y, 2007, BRIT J DERMATOL, V157, P1124, DOI 10.1111/j.1365-2133.2007.08196.x